美国食品药品监督管理局（FDA）已正式授予Alixorexton突破性疗法认定，该药物将用于治疗1型发作性睡病。这一认定旨在加速针对严重疾病且初步临床证据显示显著优于现有疗法的药物研发与审评流程。
美国食品药品监督管理局（FDA）已正式授予Alixorexton突破性疗法认定，该药物将用于治疗1型发作性睡病。这一认定旨在加速针对严重疾病且初步临床证据显示显著优于现有疗法的药物研发与审评流程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.